Veraxa Biotech Holding AG

VRXA

NASDAQHealthcareBiotechnology

企業プロフィール

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.

Veraxa Biotech Holding AG

企業プロフィール

Veraxa Biotech Holding AG

企業プロフィール

市場での位置

VRXA ニュース

Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VRXAの同業他社

GoAI で研究を続ける

企業プロフィール

市場での位置

企業プロフィール

企業プロフィール

市場での位置

企業プロフィール

市場での位置

VRXA ニュース

Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VRXAの同業他社

GoAI で研究を続ける

Veraxa Biotech Holding AG

VRXAの企業概要

企業プロフィール

Veraxa Biotech Holding AG

VRXAの企業概要

企業プロフィール

市場での位置

VRXA ニュース

Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VRXAの同業他社

GoAI で研究を続ける

VRXAの企業概要

企業プロフィール

市場での位置

VRXAの企業概要

企業プロフィール

VRXAの企業概要

企業プロフィール

市場での位置

VRXAの企業概要

企業プロフィール

市場での位置

VRXA ニュース

Micro-Cap Stock Veraxa Biotech Is Down 96% This Year. Can Next-Gen Drug Testing Save It?

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VRXAの同業他社

GoAI で研究を続ける